Q2 FY2026 EarningsQ2 FY26 beat consensus across all major financial metrics, driven by accelerated commercial adoption of ARCALYST. Revenue reached $243.6M (+55% YoY), surpassing the $226.5M expected, while Diluted EPS of $0.30 exceeded the $0.29 mean estimate. Management significantly raised FY26 ARCALYST sales guidance to $980M - $995M (vs. $930M - $945M prior), reflecting robust market penetration in recurrent pericarditis and sustained patient duration.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Kiniksa Pharmaceuticals(KNSA) the Revenue is 243.6 M (+55.36%), Beat estimate;the EBIT is 27.19 M (+34.89%), Miss estimate;the EPS is 0.3 (+30.43%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.24B55.36%
0.23B44.43%
+0.02B10.93%
EBITMiss expectations
0.03B34.89%
0.03B60.94%
-0.01B26.05%
EPSExceed expectations
0.330.43%
0.287725.10%
+0.01235.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf